BPC-157 Rotator Cuff Trial NCT07803250: What the Registry Record Shows

What is NCT07803250?

NCT07803250 is a ClinicalTrials.gov registration for a phase 1 study of BPC-157 in adults undergoing arthroscopic rotator cuff repair, sponsored by the University of Arkansas. It was first posted on 2026-09-03, lists an estimated enrollment of 30, and is not yet recruiting. The registry describes a plan, not results.

The official title is "Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery." The record was first submitted on 2026-08-12, passed quality-control review on 2026-09-01, and went public two days later. The status was last verified in September 2026. This article reports what the record says and nothing beyond it. Amino Foundry supplies BPC-157 for laboratory research only, and nothing in a registry record changes that.

What does the registry record say?

The record lists a lead sponsor, a phase, a design, one primary endpoint and estimated dates. Every field below is copied from the ClinicalTrials.gov entry as of 2026-10-19. Fields marked estimated are the sponsor's projections, not events that have happened.

Registry field	Value
NCT number	NCT07803250
Official title	Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery
Lead sponsor	University of Arkansas (no collaborators listed)
Study type and phase	Interventional, Phase 1
Design	Randomized, parallel assignment, quadruple masking
Arms	BPC-157 arm and a sham comparator arm
Enrollment	30 (estimated)
Condition	Rotator cuff tear
Primary outcome	Shoulder strength
Status	Not yet recruiting
First posted	2026-09-03
Estimated start	2027-01-01
Estimated primary completion	2027-08-01

The primary endpoint wording is specific. Isometric shoulder abduction strength is to be assessed with a handheld dynamometer, focusing on abduction and external rotation at 0 degrees of abduction. Three trials are recorded and the average peak force is the outcome value, measured by a blinded evaluator at baseline, 12 weeks and 5 months after surgery. None of these measures has been reported.

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of a human gastric juice protein. It has 15 residues, the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, the formula C₆₂H₉₈N₁₆O₂₂, a molecular weight of 1419.56 g/mol, and CAS 137525-51-0.

PubChem indexes the same formula under CID 9941957 and lists the same CAS number. Published work on the peptide has characterized its interactions with the nitric oxide system, VEGF and FGF growth factor signaling, and dopaminergic and GABAergic pathways, almost entirely in preclinical tissue and animal models. The BPC-157 research summary covers that mechanism literature in more detail. Amino Foundry also lists the BPC-157 and TB500 blend for laboratory comparison work.

Is NCT07803250 the first registered human study of BPC-157?

No. A search of ClinicalTrials.gov on 2026-10-19 for "BPC-157" and "pentadecapeptide" returns at least two earlier interventional registrations with a phase designation. Among the records that search returns, NCT07803250 is the only one with a university as lead sponsor and the only one set after orthopaedic surgery, but it is not the first registration.

NCT number	Sponsor	Phase	Setting (as registered)	Enrollment	Status	First posted
NCT02637284	PharmaCotherapia d.o.o.	Phase 1	Healthy volunteers, safety and pharmacokinetics of PCO-02	42 (estimated)	Unknown	2015-12-22
NCT07437547	Hudson Biotech	Phase 2	Acute grade II hamstring strain confirmed by MRI	120 (estimated)	Recruiting	2026-02-27
NCT07803250	University of Arkansas	Phase 1	After arthroscopic rotator cuff repair	30 (estimated)	Not yet recruiting	2026-09-03

The 2015 record names PCO-02 as a product "which active ingredient is BPC-157" and lists adverse events as its primary outcome; its status has not been updated since it was posted, which is why ClinicalTrials.gov shows it as unknown. The 2026 hamstring study lists two primary outcomes, time to return to unrestricted sport participation and the change in MRI-assessed injury volume at day 14. A further completed industry study posted on 2026-08-07 (NCT07752381) also matches a BPC-157 search but carries no phase designation.

Why is a university-sponsored registration notable?

Most of the published BPC-157 literature comes from animal and cell models, and the intervention description in this record says so directly: it states that BPC-157 "has not undergone formal human clinical trials and remains an investigational compound not approved by the FDA." A masked, randomized registration from an academic center is a different kind of document.

Three features stand out. The design is randomized and quadruple masked, meaning participants, care providers, investigators and outcome assessors are all blinded. The primary endpoint is an instrumented strength measurement rather than a questionnaire. And the sponsor is an academic institution that registered before enrollment, which is the order of operations registry rules are built around. None of that says anything about results; it describes how the question is set up.

The timing also sits inside a busy regulatory year for the peptide. The July 2026 FDA advisory committee vote on BPC-157 concerned compounding policy, not clinical evidence, and the registration does not change that analysis.

What does a ClinicalTrials.gov registration establish, and what does it not?

A registration establishes that a sponsor has publicly committed to a design: who, how many, which arms, which endpoints, and on what timeline. It does not establish that the study has started, that it will finish, or anything about what it will find. NCT07803250 has posted no results.

The record can change. Sponsors update enrollment targets, dates and status as a study moves, and the history tab on ClinicalTrials.gov preserves every version. The 2015 PCO-02 record shows the other path: a registration that was never updated and now reads as unknown. A record with an estimated start date of 2027-01-01 and an estimated primary completion of 2027-08-01 will not produce outcome data for some time, and results, if posted, would appear first in the registry's results section or in a peer-reviewed paper.

For a research reader, the practical value of the record is precision. It fixes the compound name, the design and the endpoint wording, so later reports about the study can be checked against what was planned.

What should researchers watch for next?

The next meaningful change to the record would be a status update from not yet recruiting to recruiting, followed by revisions to enrollment or dates. Those updates appear in the record's history. Results, if they come, would follow primary completion, which the sponsor currently estimates for August 2027.

Until then, characterization work on research-grade material depends on the same analytical documents as before: mass spectrometry for identity and HPLC for purity. The guide to reading a COA covers both. A registered human study does not change the identity or purity of any vial, and it does not change the status of research-grade BPC-157.

All compounds referenced in this article, including BPC-157, are supplied for research purposes only and are not for human use. Nothing here describes or endorses any use outside laboratory research. These products are not intended to diagnose, treat, cure, or prevent any disease.